Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient. Due to the variety of HCV clinical manifestations, a multidisciplinary approach along with appropriate therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, international recommendations for the therapeutic management of HCV-EHMs are needed. This implies the need to define the best criteria to use antivirals and/or other therapeutic approaches. The present recommendations, based on qualified expert experience and specific literature, will focus on etiological (antiviral) therapies and/or traditional pathogenetic treatments that still maintain their therapeutic utility.

International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement / Zignego, Anna Linda; Ramos Casals, Manuel; Ferri, Clodoveo; Saadoun, David; Arcaini, Luca; Roccatello, Dario; Antonelli, Alessandro; Desbois, Anne Claire; Comarmond, Cloe; Gragnani, Laura; Casato, Milvia; Lamprecht, Peter; Mangia, Alessandra; Tzioufas, Athanasios G; Younossi, Zobair M; Cacoub, Patrice. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 16:5(2017), pp. 523-541. [10.1016/j.autrev.2017.03.004]

International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement

FERRI, Clodoveo;
2017

Abstract

Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient. Due to the variety of HCV clinical manifestations, a multidisciplinary approach along with appropriate therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, international recommendations for the therapeutic management of HCV-EHMs are needed. This implies the need to define the best criteria to use antivirals and/or other therapeutic approaches. The present recommendations, based on qualified expert experience and specific literature, will focus on etiological (antiviral) therapies and/or traditional pathogenetic treatments that still maintain their therapeutic utility.
2017
16
5
523
541
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement / Zignego, Anna Linda; Ramos Casals, Manuel; Ferri, Clodoveo; Saadoun, David; Arcaini, Luca; Roccatello, Dario; Antonelli, Alessandro; Desbois, Anne Claire; Comarmond, Cloe; Gragnani, Laura; Casato, Milvia; Lamprecht, Peter; Mangia, Alessandra; Tzioufas, Athanasios G; Younossi, Zobair M; Cacoub, Patrice. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 16:5(2017), pp. 523-541. [10.1016/j.autrev.2017.03.004]
Zignego, Anna Linda; Ramos Casals, Manuel; Ferri, Clodoveo; Saadoun, David; Arcaini, Luca; Roccatello, Dario; Antonelli, Alessandro; Desbois, Anne Claire; Comarmond, Cloe; Gragnani, Laura; Casato, Milvia; Lamprecht, Peter; Mangia, Alessandra; Tzioufas, Athanasios G; Younossi, Zobair M; Cacoub, Patrice
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1568997217300575-main.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 888.68 kB
Formato Adobe PDF
888.68 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1138705
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 88
social impact